Novartis AG
del-brax
f acioscapulohumeral muscular dystrophy (FSHD)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for del-brax in f acioscapulohumeral muscular dystrophy (FSHD) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“topline results from these two initial cohorts were presented at the 32nd FSHD International Research Congress in June 2025.”